{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T02:00:30Z","timestamp":1766023230553,"version":"3.48.0"},"reference-count":25,"publisher":"e-Century Publishing Corporation","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/ocyr8437","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T03:09:11Z","timestamp":1746500951000},"page":"3228-3234","source":"Crossref","is-referenced-by-count":1,"title":["Tenofovir disoproxil fumarate: safe and effective option for managing high-viral-load chronic hepatitis B"],"prefix":"10.62347","volume":"17","author":[{"given":"Wenyuan","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"769","DOI":"10.14218\/jcth.2021.00209","article-title":"Guidelines for prevention and treatment of chronic hepatitis B","volume":"9","author":"Wang","year":"2021","unstructured":"Wang G and Duan Z. Guidelines for prevention and treatment of chronic hepatitis B. J Clin Transl Hepatol 2021; 9: 769-791.","journal-title":"J Clin Transl Hepatol"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Philips CA, Ahamed R, Abduljaleel JK, Rajesh S and Augustine P. Critical updates on chronic hepatitis B virus infection in 2021. Cureus 2021; 13: e19152.","DOI":"10.7759\/cureus.19152"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/jvh.13452","article-title":"Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis","volume":"28","author":"Campbell","year":"2021","unstructured":"Campbell C, Wang T, McNaughton AL, Barnes E and Matthews PC. Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis. J Viral Hepat 2021; 28: 493-507.","journal-title":"J Viral Hepat"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3390\/v15040997","article-title":"Evidence for benefits of early treatment initiation for chronic hepatitis B","volume":"15","author":"Lim","year":"2023","unstructured":"Lim YS, Kim WR, Dieterich D, Kao JH, Flaherty JF, Yee LJ, Roberts LR, Razavi H and Kennedy PTF. Evidence for benefits of early treatment initiation for chronic hepatitis B. Viruses 2023; 15: 997.","journal-title":"Viruses"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1136\/gutjnl-2011-300937","article-title":"Reasons to consider earlier treatment of chronic HBV infections","volume":"61","author":"Zoulim","year":"2012","unstructured":"Zoulim F and Mason WS. Reasons to consider earlier treatment of chronic HBV infections. Gut 2012; 61: 333-336.","journal-title":"Gut"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1016\/j.cgh.2021.07.036","article-title":"Treatment algorithm for managing chronic hepatitis B virus infection in the United States: 2021 update","volume":"20","author":"Martin","year":"2022","unstructured":"Martin P, Nguyen MH, Dieterich DT, Lau DT, Janssen HLA, Peters MG and Jacobson IM. Treatment algorithm for managing chronic hepatitis B virus infection in the United States: 2021 update. Clin Gastroenterol Hepatol 2022; 20: 1766-1775.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref6","unstructured":"Tsai E. Review of current and potential treatments for chronic hepatitis B virus infection. Gastroenterol Hepatol (N Y) 2021; 17: 367-376."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"666","DOI":"10.3748\/wjg.v27.i8.666","article-title":"New therapeutic options for persistent low-level viremia in patients with chronic hepatitis B virus infection: increase of entecavir dosage","volume":"27","author":"Yin","year":"2021","unstructured":"Yin GQ, Li J, Zhong B, Yang YF and Wang MR. New therapeutic options for persistent low-level viremia in patients with chronic hepatitis B virus infection: increase of entecavir dosage. World J Gastroenterol 2021; 27: 666-676.","journal-title":"World J Gastroenterol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1002\/hep.26301","article-title":"Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis","volume":"58","author":"Wong","year":"2013","unstructured":"Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, Iu HW, Leung JM, Lai JW, Lo AO, Chan HY and Wong VW. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013; 58: 1537-1547.","journal-title":"Hepatology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40121-020-00355-w","article-title":"Effect of entecavir on the intestinal microflora in patients with chronic hepatitis B: a controlled cross-sectional and longitudinal real-world study","volume":"10","author":"YX","year":"2021","unstructured":"Lu YX, He CZ, Wang YX, Ai ZS, Liang P and Yang CQ. Effect of entecavir on the intestinal microflora in patients with chronic hepatitis B: a controlled cross-sectional and longitudinal real-world study. Infect Dis Ther 2021; 10: 241-252.","journal-title":"Infect Dis Ther"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"763150","DOI":"10.3389\/fmolb.2021.763150","article-title":"Potential molecular targets of tenofovir disoproxil fumarate for alleviating chronic liver diseases via a non-antiviral effect in a normal mouse model","volume":"8","author":"Duan","year":"2021","unstructured":"Duan Y, Chen Z, Li H, Shen W, Zeng Y, Peng M and Hu P. Potential molecular targets of tenofovir disoproxil fumarate for alleviating chronic liver diseases via a non-antiviral effect in a normal mouse model. Front Mol Biosci 2021; 8: 763150.","journal-title":"Front Mol Biosci"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/S1473-3099(20)30692-7","article-title":"Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-controlled, parallel-group, randomised trial","volume":"21","author":"Hsu","year":"2021","unstructured":"Hsu YC, Chen CY, Chang IW, Chang CY, Wu CY, Lee TY, Wu MS, Bair MJ, Chen JJ, Chen CC, Tseng CH, Tai CM, Huang YT, Ku WH, Mo LR and Lin JT. Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-controlled, parallel-group, randomised trial. Lancet Infect Dis 2021; 21: 823-833.","journal-title":"Lancet Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"100847","DOI":"10.1016\/j.jhepr.2023.100847","article-title":"Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B","volume":"5","author":"Lim","year":"2023","unstructured":"Lim YS, Chan HLY, Ahn SH, Seto WK, Ning Q, Agarwal K, Janssen HLA, Pan CQ, Chuang WL, Izumi N, Fung S, Shalimar, Brunetto M, Hui AJ, Chang TT, Lim SG, Abramov F, Flaherty JF, Wang H, Yee LJ, Kao JH, Gane E, Hou J and Buti M. Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B. JHEP Rep 2023; 5: 100847.","journal-title":"JHEP Rep"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3350\/cmh.2021.0179","article-title":"Entecavir versus tenofovir in patients with chronic hepatitis B: enemies or partners in the prevention of hepatocellular carcinoma","volume":"27","author":"Lee","year":"2021","unstructured":"Lee SW, Choi J, Kim SU and Lim YS. Entecavir versus tenofovir in patients with chronic hepatitis B: enemies or partners in the prevention of hepatocellular carcinoma. Clin Mol Hepatol 2021; 27: 402-412.","journal-title":"Clin Mol Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.14218\/jcth.2023.00320","article-title":"Guidelines for the prevention and treatment of chronic Hepatitis B (version 2022)","volume":"11","author":"You","year":"2023","unstructured":"You H, Wang F, Li T, Xu X, Sun Y, Nan Y, Wang G, Hou J, Duan Z, Wei L, Jia J and Zhuang H; Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic Hepatitis B (version 2022). J Clin Transl Hepatol 2023; 11: 1425-1442.","journal-title":"J Clin Transl Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Shimakawa Y, Ndow G, Kaneko A, Aoyagi K, Lemoine M and Tanaka Y; PROLIFICA\/HBCRAG-RDT STUDY GROUP. Rapid point-of-care test for hepatitis B core-related antigen to diagnose high viral load in resource-limited settings. Clin Gastroenterol Hepatol 2023; 21: 1943-1946, e1942.","DOI":"10.1016\/j.cgh.2022.05.026"},{"key":"ref16","unstructured":"Zhu Y, Luo Y, Guo F, Yang K, Fan H, Liu C, Huang B, Tang X and Guan Y. Predictive value of serum HBV RNA for therapeutic effect of entecavir in patients with chronic hepatitis B. Nan Fang Yi Ke Da Xue Xue Bao 2022; 42: 1250-1255."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1093\/infdis\/jiaa739","article-title":"Association between fatty liver and cirrhosis, hepatocellular carcinoma, and hepatitis B surface antigen seroclearance in chronic hepatitis B","volume":"224","author":"Li","year":"2021","unstructured":"Li J, Yang HI, Yeh ML, Le MH, Le AK, Yeo YH, Dai CY, Barnett S, Zhang JQ, Huang JF, Trinh HN, Wong C, Wong C, Hoang JK, Cheung R, Yu ML and Nguyen MH. Association between fatty liver and cirrhosis, hepatocellular carcinoma, and hepatitis B surface antigen seroclearance in chronic hepatitis B. J Infect Dis 2021; 224: 294-302.","journal-title":"J Infect Dis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/HEP.0000000000000752","article-title":"Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: a multinational cohort study of HBeAg-positive patients","volume":"80","author":"Choi","year":"2024","unstructured":"Choi WM, Yip TC, Kim WR, Yee LJ, Brooks-Rooney C, Curteis T, Clark LJ, Jafry Z, Chen CH, Chen CY, Huang YH, Jin YJ, Jun DW, Kim JW, Park NH, Peng CY, Shin HP, Shin JW, Yang YH, Wong GL and Lim YS. Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: a multinational cohort study of HBeAg-positive patients. Hepatology 2024; 80: 428-439.","journal-title":"Hepatology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3892\/br.2020.1396","article-title":"Switching to tenofovir disoproxil fumarate in entecavir-treated chronic hepatitis B patients: a pilot randomized controlled study","volume":"14","author":"Inoue","year":"2021","unstructured":"Inoue J, Akahane T, Kobayashi T, Obara N, Umetsu T, Kakazu E, Ninomiya M, Iwata T, Sano A, Tsuruoka M, Sato K and Masamune A. Switching to tenofovir disoproxil fumarate in entecavir-treated chronic hepatitis B patients: a pilot randomized controlled study. Biomed Rep 2021; 14: 20.","journal-title":"Biomed Rep"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jceh.2020.05.003","article-title":"Tenofovir is superior to entecavir in patients with treatment-naive hepatitis B e-antigen-positive chronic hepatitis B","volume":"11","author":"Behera","year":"2021","unstructured":"Behera MK, Pati GK, Narayan J, Mishra D, Meher LK, Singh A, Uthansingh K and Sahu MK. Tenofovir is superior to entecavir in patients with treatment-naive hepatitis B e-antigen-positive chronic hepatitis B. J Clin Exp Hepatol 2021; 11: 37-44.","journal-title":"J Clin Exp Hepatol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/jvh.12313","article-title":"Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial","volume":"22","author":"Hou","year":"2015","unstructured":"Hou JL, Gao ZL, Xie Q, Zhang JM, Sheng JF, Cheng J, Chen CW, Mao Q, Zhao W, Ren H, Tan DM, Niu JQ, Chen SJ, Pan C, Tang H, Wang H, Mao YM, Jia JD, Ning Q, Xu M, Wu SM, Li J, Zhang XX, Ji Y, Dong J and Li J. Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial. J Viral Hepat 2015; 22: 85-93.","journal-title":"J Viral Hepat"},{"key":"ref22","unstructured":"Aladag H and Aladag M. Is the use of Tenofovir Dipivoxil fumarate effective and safe in preventing vertical transmission in pregnant women with chronic HBV with high viral load? Eur Rev Med Pharmacol Sci 2023; 27: 2091-2098."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/jvh.13400","article-title":"Comparison of 48-week efficacy of tenofovir vs entecavir for patients with chronic hepatitis B: a network meta-analysis","volume":"28","author":"Con","year":"2021","unstructured":"Con D, Goodwin T, Majeed A, Roberts S and Kemp W. Comparison of 48-week efficacy of tenofovir vs entecavir for patients with chronic hepatitis B: a network meta-analysis. J Viral Hepat 2021; 28: 40-50.","journal-title":"J Viral Hepat"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Liu R, Qiao J, Zhang L and Dou Z. Therapeutic effectiveness analysis of tenofovir alafenamide and tenofovir disoproxil fumarate on the treatment for chronic hepatitis B. Medicine (Baltimore) 2024; 103: e37953.","DOI":"10.1097\/MD.0000000000037953"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/4\/ajtr0163193.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:55:29Z","timestamp":1766022929000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/4\/ajtr0163193.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/ocyr8437","relation":{},"ISSN":["1943-8141"],"issn-type":[{"type":"electronic","value":"1943-8141"}],"subject":[],"published":{"date-parts":[[2025]]}}}